Apr 14, 2026 04:03PM Alpha Cognition settles payment obligations for EUR 5.2 million

Apr 1, 2026 04:31PM Alpha Cognition receives patent for traumatic brain injury treatment

Apr 1, 2026 09:51AM Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425

Feb 18, 2026 08:30AM Alpha Cognition receives US patent for ZUNVEYL dosing regimens

Nov 24, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Alpha Cognition Inc (ACOG)

Nov 14, 2025 09:46AM Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025

Oct 21, 2025 06:44AM Alpha Cognition Inc (ACOG) PT Lowered to $18 at H.C. Wainwright

Aug 22, 2025 04:04PM Alpha Cognition (ACOG) Files $250M Mixed Shelf

Aug 15, 2025 05:10PM Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025

Jul 29, 2025 08:32AM China regulator accepts Alpha Cognition's alzheimer drug application

Jul 3, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Alpha Cognition Inc (ACOG)

Jul 1, 2025 05:05PM Alpha Cognition (ACOG) announces pre-clinical data for ALPHA-1062

Jul 1, 2025 04:31PM Alpha Cognition (ACOG) Files for 2.38M Share Offering by Selling Stockholders

May 19, 2025 10:25AM Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025

Apr 30, 2025 07:30AM Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 1, 2025 04:27PM Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024

Feb 12, 2025 08:37AM Alpha Cognition (ACOG) Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

Jan 30, 2025 11:05AM Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Jan 8, 2025 08:32AM Alpha Cognition (ACOG) Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL